Compositions and methods for reducing methane emissions in ruminant populations
US-2024009291-A1 · Jan 11, 2024 · US
US9700609B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9700609-B2 |
| Application number | US-201414774461-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 18, 2014 |
| Priority date | Mar 15, 2013 |
| Publication date | Jul 11, 2017 |
| Grant date | Jul 11, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides compositions for treating or preventing T1D (T1D), the compositions comprising one or more antigen presenting cells (APC) that have been pulsed with one or more bacteria and/or components of the bacteria, wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells. The subject invention also provides a method of treating or preventing T1D in a subject, the method comprising administering APC that have been pulsed with one or more bacteria and/or components of the bacteria and wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells.
Opening claim text (preview).
We claim: 1. A method of treating or preventing type 1 Diabetes (TID), the method comprising administering to a human who has been diagnosed as having diabetes, or at risk for diabetes, an antigen presenting cell (APC) contacted with a suppressor of cytokine signaling-1 (SOCS1) protein peptide or mimetic inhibitor that antagonizes the activity of SOCS1 protein, wherein said contacting confers upon the APC the ability to inhibit the generation of diabetogenic T cells. 2. The method of claim 1 , wherein the APC is a dendritic cell (DC). 3. The method of claim 1 , wherein the peptide is selected from the group consisting of SOCS1-kinase inhibitory region (SOCS1-KIR) peptide, SOCS1-KIR2A, Tyrosine Kinase Inhibitory Peptide (TKIP), SOCS1-KIR dimer, JAK2 (1001-1013), and pJAK2(1001-1013).
Clostridium, e.g. Clostridium tetani · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Drugs for immunological or allergic disorders · CPC title
Specific bacteria not otherwise provided for · CPC title
tolerising response · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.